By proceeding, you agree to our Terms of Use and Privacy Policy.
Benjamin L. Oakes is the co-founder, President, and Chief Executive Officer at Scribe Therapeutics, a molecular engineering company focused on creating best-in-class in vivo therapies that permanently treat the underlying cause of disease.
Talks About #crispr #cellularbiology #geneticengineering
Preferred Locations #NorthAmerica
Recognised with a Nobel Prize in 2020, CRISPR has opened the floodgates for a new era of gene editing therapies, promising to transform genetic disease treatments.
